Genes, chromosomes & cancer · 2025
Novel Resistance Mechanisms to Second-Generation EGFR Tyrosine Kinase Inhibitor Afatinib and Associations With Genomic Features in NSCLC.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Fengwu, Zhao Miaoqing, Wu Qiang, Wu Wenqi, Wu Xiaoying, Ma Ya, Yin Jiani C, Yang Meng, Gao Min
Аннотация
BACKGROUND: Afatinib, an irreversible pan-ERBB family inhibitor, has demonstrated promising efficacy in non-small cell lung cancer (NSCLC) patients with uncommon EGFR activating mutations. However, besides the acquisition of the secondary T790M mutation, other resistance mechanisms to afatinib remain to be explored.
MATERIALS AND METHODS: This study retrospectively included 37 NSCLC patients harboring either EGFR or ERBB2 activating mutations, who had received afatinib as first-line treatment. Targeted next-generation sequencing data on the baseline and post-progression samples were subjected to analysis. Comparative analyses of clinical parameters and genomic features were performed.
RESULTS: Overall, the progression-free survival of the EGFR-mutated patients on first-line afatinib was longer than that of the ERBB2-positive patients (hazard ratio = 0.35 [95% confidence interval = 0.15-0.79], p = 0.008). Primary resistance was associated with the presence of exon 20 insertion mutation (p = 0.011), higher tumor mutational burden (p = 0.009), and higher proportion of APOBEC signature (p = 0.012), which were all enriched in the ERBB2-mutated cohort. We further characterized acquired resistance to afatinib and discovered that baseline EGFR exon 19 deletions and higher levels of chromosomal instability and age-related mutational signatures would contribute to the development of known resistance mechanisms such as EGFR T790M or MET amplification. We also report gaining EGFR activating mutations and losing CDKN2A, NF1, or the original ERBB2 mutations as novel resistance mechanisms to afatinib for ERBB2-mutated patients.
CONCLUSION: The study identified multiple genomic characteristics associated with primary and secondary resistance to first-line afatinib treatment in EGFR- and ERBB2-positive subpopulations.
MATERIALS AND METHODS: This study retrospectively included 37 NSCLC patients harboring either EGFR or ERBB2 activating mutations, who had received afatinib as first-line treatment. Targeted next-generation sequencing data on the baseline and post-progression samples were subjected to analysis. Comparative analyses of clinical parameters and genomic features were performed.
RESULTS: Overall, the progression-free survival of the EGFR-mutated patients on first-line afatinib was longer than that of the ERBB2-positive patients (hazard ratio = 0.35 [95% confidence interval = 0.15-0.79], p = 0.008). Primary resistance was associated with the presence of exon 20 insertion mutation (p = 0.011), higher tumor mutational burden (p = 0.009), and higher proportion of APOBEC signature (p = 0.012), which were all enriched in the ERBB2-mutated cohort. We further characterized acquired resistance to afatinib and discovered that baseline EGFR exon 19 deletions and higher levels of chromosomal instability and age-related mutational signatures would contribute to the development of known resistance mechanisms such as EGFR T790M or MET amplification. We also report gaining EGFR activating mutations and losing CDKN2A, NF1, or the original ERBB2 mutations as novel resistance mechanisms to afatinib for ERBB2-mutated patients.
CONCLUSION: The study identified multiple genomic characteristics associated with primary and secondary resistance to first-line afatinib treatment in EGFR- and ERBB2-positive subpopulations.